Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03787498 · ClinicalTrials.gov registry record · Phase 1
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
A Phase 1 study of Relapsed Acute Myeloid Leukemia (AML) and Refractory Acute Myeloid Leukemia (AML), sponsored by Opna Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 6
- Study locations
NCT03787498 is a Phase 1 study of Relapsed Acute Myeloid Leukemia (AML) and Refractory Acute Myeloid Leukemia (AML) that has completed, run by Opna Bio. The registered enrollment target is 22 participants. The trial reports 6 study locations across 6 states.
The verdict
NCT03787498, a Phase 1 study of Relapsed Acute Myeloid Leukemia (AML) and Refractory Acute Myeloid Leukemia (AML), has completed, sponsored by Opna Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Conditions Studied
Interventions
- DRUG PLX2853
Study Locations (6)
Georgia
- Northside Hospital - Atlanta
Maryland
- Sidney Kimmel Comprehensive Cancer At Johns Hopkins - Baltimore
New York
- NewYork-Presbyterian / Weill Cornell Medical Center - New York
Ohio
- Ohio State University Medical Center - Columbus
Oregon
- Oregon Health and Sciences University - Portland
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-03-19 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03787498
The ClinicalTrials.gov registry entry for NCT03787498 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Opna Bio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Relapsed Acute Myeloid Leukemia (AML) appearing as the primary indexed condition, and to 1 intervention - of which PLX2853 is the first listed.
NCT03787498 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Georgia, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT03787498 about?
NCT03787498 is a clinical study titled "A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome". The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
What is the current status of trial NCT03787498?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2019-03-19. Estimated completion is 2021-06-30.
What conditions does trial NCT03787498 study?
This clinical trial studies the following conditions: Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS).
What interventions are being tested in trial NCT03787498?
The interventions under investigation include: PLX2853 (DRUG).
Who is sponsoring clinical trial NCT03787498?
This trial is sponsored by Opna Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03787498 being conducted?
This trial has 6 study locations across Georgia, Maryland, New York, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed Acute Myeloid Leukemia (AML)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Relapsed Acute Myeloid Leukemia (AML)
All registered trials for this condition
Refractory Acute Myeloid Leukemia (AML)
All registered trials for this condition
Georgia
All trials with a study site in Georgia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.